Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2014, Article ID 102736, 13 pages
http://dx.doi.org/10.1155/2014/102736
Review Article

Can Vascular Endothelial Growth Factor and Microvessel Density Be Used as Prognostic Biomarkers for Colorectal Cancer? A Systematic Review and Meta-Analysis

Department of Epidemiology, Public Health College, Harbin Medical University, 157 Baojian Street, Nangang District, Harbin, Heilongjiang 150081, China

Received 11 November 2013; Accepted 29 January 2014; Published 27 March 2014

Academic Editors: E. Z. Dajani and C. Tosetti

Copyright © 2014 Yibaina Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. V. Barresi, C. di Gregorio, L. Regiani-Bonetti, M. Ponz-de Leon, G. Barresi, and E. Vitarelli, “Stage I colorectal carcinoma: VEGF immunohistochemical expression, microvessel density, and their correlation with clinical outcome,” Virchows Archiv, vol. 457, no. 1, pp. 11–19, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. N. Ferrara, “VEGF and the quest for tumour angiogenesis factors,” Nature Reviews Cancer, vol. 2, no. 10, pp. 795–803, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Yodavudh, S. Tangjitgamol, and S. Puangsa-art, “Prognostic significance of microvessel density and mast cell density for the survival of Thai patients with primary colorectal cancer,” Journal of the Medical Association of Thailand, vol. 91, no. 5, pp. 723–732, 2008. View at Google Scholar · View at Scopus
  4. D. W. Leung, G. Cachianes, W.-J. Kuang, D. V. Goeddel, and N. Ferrara, “Vascular endothelial growth factor is a secreted angiogenic mitogen,” Science, vol. 246, no. 4935, pp. 1306–1309, 1989. View at Google Scholar · View at Scopus
  5. M. Guba, H. Seeliger, A. Kleespies, K.-W. Jauch, and C. Bruns, “Vascular endothelial growth factor in colorectal cancer,” International Journal of Colorectal Disease, vol. 19, no. 6, pp. 510–517, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. H. Hurwitz, L. Fehrenbacher, W. Novotny et al., “Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer,” The New England Journal of Medicine, vol. 350, no. 23, pp. 2335–2342, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. L. B. Saltz, S. Clarke, E. Díaz-Rubio et al., “Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study,” Journal of Clinical Oncology, vol. 26, no. 12, pp. 2013–2019, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. B. J. Giantonio, P. J. Catalano, N. J. Meropol et al., “Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200,” Journal of Clinical Oncology, vol. 25, no. 12, pp. 1539–1544, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. F. F. Kabbinavar, J. Schulz, M. McCleod et al., “Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial,” Journal of Clinical Oncology, vol. 23, no. 16, pp. 3697–3705, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. G. Des Guetz, B. Uzzan, P. Nicolas et al., “Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature,” British Journal of Cancer, vol. 94, no. 12, pp. 1823–1832, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. S. L. Spruance, J. E. Reid, M. Grace, and M. Samore, “Hazard ratio in clinical trials,” Antimicrobial Agents and Chemotherapy, vol. 48, no. 8, pp. 2787–2792, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. E. Steels, M. Paesmans, T. Berghmans et al., “Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis,” European Respiratory Journal, vol. 18, no. 4, pp. 705–719, 2001. View at Publisher · View at Google Scholar · View at Scopus
  13. B. Uzzan, P. Nicolas, M. Cucherat, and G.-Y. Perret, “Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis,” Cancer Research, vol. 64, no. 9, pp. 2941–2955, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. R. DerSimonian and N. Laird, “Meta-analysis in clinical trials,” Controlled Clinical Trials, vol. 7, no. 3, pp. 177–188, 1986. View at Google Scholar · View at Scopus
  15. C. B. Begg and M. Mazumdar, “Operating characteristics of a rank correlation test for publication bias,” Biometrics, vol. 50, no. 4, pp. 1088–1101, 1994. View at Publisher · View at Google Scholar · View at Scopus
  16. G. M. Boxer, E. Tsiompanou, T. Levine, R. Watson, and R. H. J. Begent, “Immunohistochemical expression of vascular endothelial growth factor and microvessel counting as prognostic indicators in node-negative colorectal cancer,” Tumor Biology, vol. 26, no. 1, pp. 1–8, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. F. Cianchi, A. Palomba, L. Messerini et al., “Tumor angiogenesis in lymph node-negative rectal cancer: correlation with clinicopathological parameters and prognosis,” Annals of Surgical Oncology, vol. 9, no. 1, pp. 20–26, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. Y. S. Hong, H. J. Cho, S. Y. Kim et al., “Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancer,” BMC cancer, vol. 9, article 246, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Giralt, B. Navalpotro, E. Hermosilla et al., “Prognostic significance of vascular endothelial growth factor and cyclooxygenase-2 in patients with rectal cancer treated with preoperative radiotherapy,” Oncology, vol. 71, no. 5-6, pp. 312–319, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Miyagawa, S. Miwa, J. Soeda, A. Kobayashi, and S. Kawasaki, “Morphometric analysis of liver macrophages in patients with colorectal liver metastasis,” Clinical and Experimental Metastasis, vol. 19, no. 2, pp. 119–125, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. Y.-C. Chung, Y.-C. Hou, C.-N. Chang, and T.-H. Hseu, “Expression and prognostic significance of angiopoietin in colorectal carcinoma,” Journal of Surgical Oncology, vol. 94, no. 7, pp. 631–638, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. R. Rajaganeshan, D. G. Jayne, H. Z. Malik et al., “Biological characteristics and behaviour of putatively curatively resected colorectal liver metastases,” European Journal of Surgical Oncology, vol. 34, no. 4, pp. 439–444, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Nanashima, K. Shibata, T. Nakayama et al., “Clinical significance of microvessel count in patients with metastatic liver cancer originating from colorectal carcinoma,” Annals of Surgical Oncology, vol. 16, no. 8, pp. 2130–2137, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. Y. Toiyama, Y. Inoue, S. Saigusa et al., “Gene expression profiles of epidermal growth factor receptor, vascular endothelial growth factor and hypoxia-inducible factor-1 with special reference to local responsiveness to neoadjuvant chemoradiotherapy and disease recurrence after rectal cancer surgery,” Clinical Oncology, vol. 22, no. 4, pp. 272–280, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. S.-C. Wei, J.-T. Liang, P.-N. Tsao, F.-J. Hsieh, S.-C. Yu, and J.-M. Wong, “Preoperative serum placenta growth factor level is a prognostic biomarker in colorectal cancer,” Diseases of the Colon and Rectum, vol. 52, no. 9, pp. 1630–1636, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. K. A. Kwon, S. H. Kim, S. Y. Oh et al., “Clinical significance of preoperative serum vascular endothelial growth factor, interleukin-6, and C-reactive protein level in colorectal cancer,” BMC Cancer, vol. 10, article 203, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. T. Miyazaki, N. Okada, K. Ishibashi et al., “Clinical significance of plasma level of vascular endothelial growth factor-C in patients with colorectal cancer,” Japanese Journal of Clinical Oncology, vol. 38, no. 12, pp. 839–843, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. S.-I. Ishigami, S. Arii, M. Furutani et al., “Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer,” British Journal of Cancer, vol. 78, no. 10, pp. 1379–1384, 1998. View at Google Scholar · View at Scopus
  29. D. Cao, M. Hou, Y.-S. Guan, M. Jiang, Y. Yang, and H.-F. Gou, “Expression of HIF-1alpha and VEGF in colorectal cancer: association with clinical outcomes and prognostic implications,” BMC Cancer, vol. 9, article 432, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. P. Ferroni, A. Spila, F. Martini et al., “Prognostic value of vascular endothelial growth factor tumor tissue content of colorectal cancer,” Oncology, vol. 69, no. 2, pp. 145–153, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. J.-F. Liang, H.-K. Wang, H. Xiao et al., “Relationship and prognostic significance of SPARC and VEGF protein expression in colon cancer,” Journal of Experimental and Clinical Cancer Research, vol. 29, no. 1, article 71, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. E. Kaio, S. Tanaka, Y. Kitadai et al., “Clinical significance of angiogenic factor expression at the deepest invasive site of advanced colorectal carcinoma,” Oncology, vol. 64, no. 1, pp. 61–73, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. A. A. Khorana, C. K. Ryan, C. Cox, S. Eberly, and D. M. Sahasrabudhe, “Vascular endothelial growth factor, CD68, and epidermal growth factor receptor expression and survival in patients with stage II and stage III colon carcinoma: a role for the host response in prognosis,” Cancer, vol. 97, no. 4, pp. 960–968, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Tamura, M. Oda, Y. Tsunezuka, I. Matsumoto, K. Kawakami, and G. Watanabe, “Vascular endothelial growth factor expression in metastatic pulmonary tumor from colorectal carcinoma: utility as a prognostic factor,” Journal of Thoracic and Cardiovascular Surgery, vol. 128, no. 4, pp. 517–522, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. J. D. White, P. W. Hewett, D. Kosuge et al., “Vascular endothelial growth factor-D expression is an independent prognostic marker for survival in colorectal carcinoma,” Cancer Research, vol. 62, no. 6, pp. 1669–1675, 2002. View at Google Scholar · View at Scopus
  36. M. Kojima, A. Shiokawa, N. Ohike et al., “Clinical significance of nuclear morphometry at the invasive front of T1 colorectal cancer and relation to expression of VEGF-A and VEGF-C,” Oncology, vol. 68, no. 2-3, pp. 230–238, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. A. A. Alabi, A. Suppiah, L. A. Madden, J. R. Monson, and J. Greenman, “Preoperative serum vascular endothelial growth factor-A is a marker for subsequent recurrence in colorectal cancer patients,” Diseases of the Colon and Rectum, vol. 52, no. 5, pp. 993–999, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. Z.-G. Zhou, X.-J. Wu, L.-R. Li et al., “A multivariate analysis of prognostic determinants for stages II and III colorectal cancer in 141 patients,” Chinese Medical Journal, vol. 124, no. 14, pp. 2132–2135, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. K. Zafirellis, G. Agrogiannis, A. Zachaki, K. Gravani, A. Karameris, and C. Kombouras, “Prognostic significance of VEGF expression evaluated by quantitative immunohistochemical analysis in colorectal cancer,” Journal of Surgical Research, vol. 147, no. 1, pp. 99–107, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. J. Chen, Q. Li, C. Wang, J. Wu, and G. Zhao, “Prognostic significance of c-erbb-2 and vascular endothelial growth factor in colorectal liver metastases,” Annals of Surgical Oncology, vol. 17, no. 6, pp. 1555–1563, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. C. Zhang, L. Hao, L. Wang et al., “Elevated IGFIR expression regulating VEGF and VEGF-C predicts lymph node metastasis in human colorectal cancer,” BMC Cancer, vol. 10, article 184, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Lin, H.-Z. Lin, S.-P. Ma, P. Ji, D. Xie, and J.-X. Yu, “Vascular endothelial growth factor-A and -C: expression and correlations with lymphatic metastasis and prognosis in colorectal cancer,” Medical Oncology, vol. 28, no. 1, pp. 151–158, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. H. Amaya, N. Tanigawa, C. Lu et al., “Association of vascular endothelial growth factor expression with tumor angiogenesis, survival and thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in human colorectal cancer,” Cancer Letters, vol. 119, no. 2, pp. 227–235, 1997. View at Publisher · View at Google Scholar · View at Scopus
  44. Y. Harada, Y. Ogata, and K. Shirouzu, “Expression of vascular endothelial growth factor and its receptor KDR (kinase domain-containing receptor)/Flk-1 (fetal liver kinase-1) as prognostic factors in human colorectal cancer,” International Journal of Clinical Oncology, vol. 6, no. 5, pp. 221–228, 2001. View at Google Scholar · View at Scopus
  45. J.-C. Lee, N.-H. Chow, S.-T. Wang, and S.-M. Huang, “Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients,” European Journal of Cancer, vol. 36, no. 6, pp. 748–753, 2000. View at Publisher · View at Google Scholar · View at Scopus
  46. S. Zheng, M.-Y. Han, Z.-X. Xiao, J.-P. Peng, and Q. Dong, “Clinical significance of vascular endothelial growth factor expression and neovascularization in colorectal carcinoma,” World Journal of Gastroenterology, vol. 9, no. 6, pp. 1227–1230, 2003. View at Google Scholar · View at Scopus
  47. A.-M. Ochs, L. Wong, V. Kakani et al., “Expression of vascular endothelial growth factor and HER2/neu in stage II colon cancer and correlation with survival,” Clinical Colorectal Cancer, vol. 4, no. 4, pp. 262–267, 2004. View at Google Scholar · View at Scopus
  48. S. M. Kang, K. Maeda, N. Onoda et al., “Combined analysis of p53 and vascular endothelial growth factor expression in colorectal carcinoma for determination of tumor vascularity and liver metastasis,” International Journal of Cancer, vol. 74, pp. 502–507, 1997. View at Google Scholar
  49. G. E. Theodoropoulos, A. C. Lazaris, V. E. Theodoropoulos et al., “Hypoxia, angiogenesis and apoptosis markers in locally advanced rectal cancer,” International Journal of Colorectal Disease, vol. 21, no. 3, pp. 248–257, 2006. View at Publisher · View at Google Scholar · View at Scopus
  50. S. Shinji, Z. Naito, T. Ishiwata et al., “Neuroendocrine cell differentiation of poorly differentiated colorectal adenocarcinoma correlates with liver metastasis,” International Journal of Oncology, vol. 29, no. 2, pp. 357–364, 2006. View at Google Scholar · View at Scopus
  51. E. Kaio, S. Tanaka, S. Oka et al., “Clinical significance of thrombospondin-1 expression in relation to vascular endothelial growth factor and interleukin-10 expression at the deepest invasive tumor site of advanced colorectal carcinoma,” International Journal of Oncology, vol. 23, no. 4, pp. 901–911, 2003. View at Google Scholar · View at Scopus
  52. A. M. Jubb, H. I. Hurwitz, W. Bai et al., “Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 24, no. 2, pp. 217–227, 2006. View at Publisher · View at Google Scholar · View at Scopus
  53. L. R. Moreira, A. A. Schenka, P. Latuf-Filho et al., “Immunohistochemical analysis of vascular density and area in colorectal carcinoma using different markers and comparison with clinicopathologic prognostic factors,” Tumor Biology, vol. 32, no. 3, pp. 527–534, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. M. Gulubova and T. Vlaykova, “Prognostic significance of mast cell number and microvascular density for the survival of patients with primary colorectal cancer,” Journal of Gastroenterology and Hepatology, vol. 24, no. 7, pp. 1265–1275, 2009. View at Publisher · View at Google Scholar · View at Scopus
  55. P. B. Vermeulen, G. G. van den Eynden, P. Huget et al., “Prospective study of intratumoral microvessel density, p53 expression and survival in colorectal cancer,” British Journal of Cancer, vol. 79, no. 2, pp. 316–322, 1999. View at Publisher · View at Google Scholar · View at Scopus
  56. T. Sternfeld, H. D. Foss, M. Kruschewski, and N. Runkel, “The prognostic significance of tumor vascularization in patients with localized colorectal cancer,” International Journal of Colorectal Disease, vol. 14, no. 6, pp. 272–276, 1999. View at Google Scholar · View at Scopus
  57. N. Tanigawa, H. Amaya, M. Matsumura et al., “Tumor anglogenesis and mode of metastasis in patients with colorectal cancer,” Cancer Research, vol. 57, no. 6, pp. 1043–1046, 1997. View at Google Scholar · View at Scopus
  58. A. A. Romani, A. F. Borghetti, P. del Rio, M. Sianesi, and P. Soliani, “The risk of developing metastatic disease in colorectal cancer is related to CD105-positive vessel count,” Journal of Surgical Oncology, vol. 93, no. 6, pp. 446–455, 2006. View at Publisher · View at Google Scholar · View at Scopus
  59. Y. Takebayashi, S. I. Akiyama, S. Akiba et al., “Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma,” Journal of the National Cancer Institute, vol. 88, pp. 1110–1117, 1996. View at Google Scholar
  60. T. Hasebe, S. Sasaki, M. Sugitoh, M. Ono, N. Saitoh, and A. Ochiai, “Proliferative activities of tumor stromal cells play important roles in tumor thickness and progression of T3 ulcerative-type colorectal cancer,” Virchows Archiv, vol. 442, no. 6, pp. 569–576, 2003. View at Google Scholar · View at Scopus
  61. S. Svagzdys, V. Lesauskaite, D. Pavalkis, I. Nedzelskiene, D. Pranys, and A. Tamelis, “Microvessel density as new prognostic marker after radiotherapy in rectal cancer,” BMC Cancer, vol. 9, article 95, 2009. View at Publisher · View at Google Scholar · View at Scopus
  62. G. Yan, X.-Y. Zhou, S.-J. Cai, G.-H. Zhang, J.-J. Peng, and X. Du, “Lymphangiogenic and angiogenic microvessel density in human primary sporadic colorectal carcinoma,” World Journal of Gastroenterology, vol. 14, no. 1, pp. 101–107, 2008. View at Publisher · View at Google Scholar · View at Scopus
  63. Y. Yonenaga, A. Mori, H. Onodera et al., “Absence of smooth muscle actin-positive pericyte coverage of tumor vessels correlates with hematogenous metastasis and prognosis of colorectal cancer patients,” Oncology, vol. 69, no. 2, pp. 159–166, 2005. View at Publisher · View at Google Scholar · View at Scopus
  64. C. Tarta, C. R. Teixeira, S. Tanaka, K. Haruma, C. Chiele-Neto, and V. D. da Silva, “Angiogenesis in advanced colorectal adenocarcinoma with special reference to tumoral invasion,” Arquivos de Gastroenterologia, vol. 39, no. 1, pp. 32–38, 2002. View at Google Scholar · View at Scopus
  65. N. Pietra, L. Sarli, P. Caruana et al., “Is tumour angiogenesis a prognostic factor in patients with colorectal cancer and no involved nodes?” European Journal of Surgery, vol. 166, no. 7, pp. 552–556, 2000. View at Google Scholar · View at Scopus
  66. H. J. Choi, M. S. Hyun, G. J. Jung, S. S. Kim, and S. H. Hong, “Tumor angiogenesis as a prognostic predictor in colorectal carcinoma with special reference to mode of metastasis and recurrence,” Oncology, vol. 55, no. 6, pp. 575–581, 1998. View at Publisher · View at Google Scholar · View at Scopus
  67. S. Tomisaki, S. Ohno, Y. Ichiyoshi, H. Kuwano, Y. Maehara, and K. Sugimachi, “Microvessel quantification and its possible relation with liver metastasis in colorectal cancer,” Cancer, vol. 77, pp. 1722–1728, 1996. View at Publisher · View at Google Scholar
  68. N. Minagawa, Y. Nakayama, K. Hirata et al., “Correlation of plasma level and immunohistochemical expression of vascular endothelial growth factor in patients with advanced colorectal cancer,” Anticancer Research, vol. 22, no. 5, pp. 2957–2964, 2002. View at Google Scholar · View at Scopus
  69. Y. Takebayashi, S. I. Akiyama, K. Yamada, S. Akiba, and T. Aikou, “Angiogenesis as an unfavorable prognostic factor in human colorectal carcinoma,” Cancer, vol. 78, pp. 226–231, 1996. View at Google Scholar
  70. N. Sharifi, K. Ghaffarzadegan, H. Ayatollahi, M. T. Shakeri, M. H. Sadeghian, and J. B. Azari, “Evaluation of angiogenesis in colorectal carcinoma by CD34 immunohistochemistry method and its correlation with clinicopathologic parameters,” Acta Medica Iranica, vol. 47, no. 3, pp. 161–164, 2009. View at Google Scholar · View at Scopus
  71. S. Rasheed, A. L. Harris, P. P. Tekkis et al., “Assessment of microvessel density and carbonic anhydrase-9 (CA-9) expression in rectal cancer,” Pathology Research and Practice, vol. 205, no. 1, pp. 1–9, 2009. View at Publisher · View at Google Scholar · View at Scopus
  72. N. Teranishi, Z. Naito, T. Ishiwata et al., “Identification of neovasculature using nestin in colorectal cancer,” International Journal of Oncology, vol. 30, no. 3, pp. 593–603, 2007. View at Google Scholar · View at Scopus
  73. A. Nanashima, M. Ito, I. Sekine et al., “Significance of angiogenic factors in liver metastatic tumors originating from colorectal cancers,” Digestive Diseases and Sciences, vol. 43, no. 12, pp. 2634–2640, 1998. View at Publisher · View at Google Scholar · View at Scopus
  74. M. F. Acikalin, Ü. Öner, I. Topçu, B. Yaşar, H. Kiper, and E. Çolak, “Tumour angiogenesis and mast cell density in the prognostic assessment of colorectal carcinomas,” Digestive and Liver Disease, vol. 37, no. 3, pp. 162–169, 2005. View at Publisher · View at Google Scholar · View at Scopus
  75. P. Zhan, J. Wang, X.-J. Lv et al., “Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis,” Journal of Thoracic Oncology, vol. 4, no. 9, pp. 1094–1103, 2009. View at Publisher · View at Google Scholar · View at Scopus
  76. R. A. Smith, J. Tang, C. Tudur-Smith, J. P. Neoptolemos, and P. Ghaneh, “Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer,” British Journal of Cancer, vol. 104, no. 9, pp. 1440–1451, 2011. View at Publisher · View at Google Scholar · View at Scopus
  77. S. J. Schoenleber, D. M. Kurtz, J. A. Talwalkar, L. R. Roberts, and G. J. Gores, “Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis,” British Journal of Cancer, vol. 100, no. 9, pp. 1385–1392, 2009. View at Publisher · View at Google Scholar · View at Scopus
  78. J. Chen, T. Li, Y. Wu et al., “Prognostic significance of vascular endothelial growth factor expression in gastric carcinoma: a meta-analysis,” Journal of Cancer Research and Clinical Oncology, vol. 137, no. 12, pp. 1799–1812, 2011. View at Publisher · View at Google Scholar · View at Scopus
  79. N. Ferrara, “Vascular endothelial growth factor: basic science and clinical progress,” Endocrine Reviews, vol. 25, no. 4, pp. 581–611, 2004. View at Publisher · View at Google Scholar · View at Scopus
  80. L. G. Presta, H. Chen, S. J. O'Connor et al., “Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders,” Cancer Research, vol. 57, no. 20, pp. 4593–4599, 1997. View at Google Scholar · View at Scopus
  81. H. Hurwitz, “Integrating the anti-VEGF—a humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer,” Clinical Colorectal Cancer, vol. 4, supplement 2, pp. S62–S68, 2004. View at Google Scholar · View at Scopus
  82. L. Saltz, “Management of metastatic colorectal cancer: the impact of clinical trials reported at ASCO 2007,” Community Oncology, vol. 5, no. 1, pp. 37–42, 2008. View at Google Scholar · View at Scopus
  83. F. F. Kabbinavar, J. Hambleton, R. D. Mass, H. I. Hurwitz, E. Bergsland, and S. Sarkar, “Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 23, no. 16, pp. 3706–3712, 2005. View at Publisher · View at Google Scholar · View at Scopus
  84. Y. Cao, A. Tan, F. Gao, L. Liu, C. Liao, and Z. Mo, “A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer,” International Journal of Colorectal Disease, vol. 24, no. 6, pp. 677–685, 2009. View at Publisher · View at Google Scholar · View at Scopus